TLPHHIGH SIGNALFINANCIAL10-K

TLPH underwent a major capital restructuring with share count increasing 193% to 50M shares, substantially strengthening the balance sheet through debt reduction and equity infusion.

The dramatic increase in outstanding shares from 17.1M to 50M indicates a significant equity raise or conversion event that funded debt reduction from $13.8M to $5.8M and improved stockholders' equity by 113%. This represents a major recapitalization that substantially strengthened TLPH's financial position but likely resulted in significant dilution for existing shareholders.

Comparing 2026-03-23 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

TLPH executed a major balance sheet transformation, with current assets surging 122% to $20.9M and stockholders' equity more than doubling to $17M, while total debt declined 58% to $5.8M and interest expense plummeted 88%. Despite cash declining 34% to $5.9M and revenue dropping 22% to $475K, the overall financial picture signals a successful recapitalization that dramatically improved the company's capital structure and reduced financial risk. The substantial increase in share count suggests this strength came at the cost of significant dilution to existing equity holders.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+121.9%
$9.4M$20.9M

Current assets grew 121.9% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+112.9%
$8.0M$17.0M

Equity base grew 112.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+93.1%
$160K$309K

Receivables surged 93.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Interest Expense
P&L
-88.4%
$1.2M$134K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Assets
Balance Sheet
+63%
$18.2M$29.7M

Asset base grew 63% — expansion through organic growth, acquisitions, or capital deployment.

Total Debt
Balance Sheet
-58.2%
$13.8M$5.8M

Debt reduced 58.2% — deleveraging strengthens balance sheet and reduces financial risk.

Current Liabilities
Balance Sheet
+43.9%
$2.6M$3.8M

Current liabilities surged 43.9% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-33.5%
$8.9M$5.9M

Cash declined 33.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+23.9%
$10.2M$12.7M

Liabilities increased 23.9% — monitor debt-to-equity ratio and interest coverage.

Revenue
P&L
-21.9%
$608K$475K

Revenue softened 21.9% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-31
ADDED
As of March 18, 2026, the number of outstanding shares of the registrant s common stock was 50,049,824 .
Fedsyra is a trademark, and Niyad and Zalviso are registered trademarks, all owned by Talphera, Inc.
In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the filing date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
+7 more — sign up free →
REMOVED
As of March 17, 2025, the number of outstanding shares of the registrant s common stock was 17,098,345 .
Niyad and Fedsyra are trademarks, and Zalviso are registered trademarks, all owned by Talphera, Inc.
Our common stock may be delisted from The Nasdaq Global Market if we cannot regain compliance with Nasdaq s continued listing requirements, which could limit our ability to raise additional capital in the future, limit our investors ability to make transactions in our common stock and subject us to additional trading restrictions.
We may fail to realize the benefits expected from our acquisition of Lowell Therapeutics, Inc., or Lowell, which could adversely affect our stock price.
We may fail to properly conduct and/or successfully complete our clinical trial for our lead product candidate, Niyad .
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →